Anti-CD19 CAR T cell therapy (Shanghai GeneChem)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAnti-CD19 CAR T cell therapy (Shanghai GeneChem)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShanghai Genechem Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShanghai Genechem Co Ltd
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A